Akèy › Tit travay › Manager, Regulatory Affairs
Manager, Regulatory Affairs: Salè H-1B
72 aplikasyon kondisyon travay te itilize tit travay Manager, Regulatory Affairs. Salè baz medyàn ofri $132,288; mwatye mitan $119,706–$144,000.
Demann (LCA)72
Salè medyan ofri$132,288
Mwatye salè yo$119,706–$144,000
10yèm–90yèm pousantaj$110,000–$159,500
Avoka imigrasyon, rekritè oswa anplwayè? Mete sèvis ou an tèt paj sa a — $99 pou 30 jou →
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|
| Edwards Lifesciences LLC | 7 | $132,288 |
| Teva Pharmaceuticals USA, Inc. | 6 | $127,182 |
| ReCor Medical, Inc. | 2 | $150,000 |
| Collegium Pharmaceutical, Inc. | 2 | $158,121 |
| Thermo Fisher Scientific Inc. | 2 | $122,377 |
| Lonza Houston Inc | 2 | $137,511 |
| Becton, Dickinson and Company | 2 | $144,000 |
| Cardinal Health | 2 | $137,002 |
| Eikon Therapeutics, Inc. | 2 | $124,654 |
| Terumo Medical Corporation | 2 | $133,832 |
| Xiromed, LLC | 2 | $125,169 |
| Verastem Inc. | 1 | $133,848 |
| Karyopharm Therapeutics Inc. | 1 | $120,000 |
| Eugia US Manufacturing LLC | 1 | — |
| Emergent Travel Health Inc. | 1 | $136,490 |
| Amarin Pharma Inc. | 1 | $175,000 |
| Bavarian Nordic Inc. | 1 | $134,430 |
| Daiichi Sankyo, Inc. | 1 | $135,000 |
| BeiGene USA, Inc. | 1 | $130,000 |
| McKesson Corporation | 1 | $129,377 |
| Baxter Healthcare Corporation (USA) | 1 | $110,000 |
| Chanel, Inc. | 1 | $110,000 |
| Masimo Corporation | 1 | $127,192 |
| Alvogen Group Inc. | 1 | $142,000 |
| Alnylam US, Inc. | 1 | $140,000 |
| Emergent Product Development Gaithersburg Inc. | 1 | $140,000 |
| Cosette Pharmaceuticals, Inc. | 1 | $85,000 |
| Zydus Pharmaceuticals USA, Inc. | 1 | $112,000 |
| iRhythm Technologies, Inc. | 1 | $187,959 |
| Riconpharma, LLC | 1 | $125,000 |
| Gilead Sciences, Inc. | 1 | $157,991 |
| Helen of Troy Nevada Corporation | 1 | $115,000 |
| Hikma Pharmaceuticals USA Inc. | 1 | $120,453 |
| Bausch Health US, LLC | 1 | $112,235 |
| Apellis Pharmaceuticals Inc. | 1 | $148,384 |
| ChemWerth Inc. | 1 | $113,443 |
| FUJIFILM Sonosite, Inc. | 1 | $137,898 |
| Relay Therapeutics, Inc. | 1 | $100,000 |
| Penumbra, Inc. | 1 | $123,469 |
| Alphatec Spine Inc. | 1 | $150,000 |
| Gen-Probe Incorporated | 1 | $114,691 |
| Syner-G BioPharma Group LLC | 1 | $122,926 |
| Eugia US LLC | 1 | $124,000 |
| AdvaGen Pharma, Ltd. | 1 | $145,000 |
| Synaptic Medical Corp. | 1 | $180,000 |
| Intuitive Surgical Operations, Inc. | 1 | $213,428 |
| CRISPR Therapeutics, Inc. | 1 | $1,524,000 |
| St. Jude Medical, Cardiology Division, Inc. | 1 | $155,000 |
| Revolution Medicines, Inc. | 1 | $159,500 |
| Navinta III Inc. | 1 | $90,000 |
| Aveva Drug Delivery Systems, Inc. | 1 | $110,000 |
| West Pharmaceutical Services, Inc. | 1 | $119,350 |
Pa nivo salè
| Nivo revni | Salè medyan |
|---|
| Nivo I (antre) | $124,004 |
| Nivo II (kalifye) | $134,430 |
| Nivo III (eksperyans) | $136,000 |
| Nivo IV (plen kompetans) | $126,672 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Pa ane fiskal
| Ane fiskal | LCA | Salè medyan |
|---|
| FY2023 | 16 | $133,865 |
| FY2024 | 18 | $128,148 |
| FY2025 | 25 | $132,288 |
| FY2026 | 12 | $135,532 |
Vil yo
- Irvine, CA8
- East Windsor, NJ3
- Parsippany, NJ3
- Palo Alto, CA2
- Redwood City, CA2
- Bridgewater, NJ2
- Stoughton, MA2
- San Diego, CA2
- Houston, TX2
- Santa Ana, CA2
- Dublin, OH2
- Cambridge, MA2
- Somerset, NJ2
- West Chester, PA2
- Carlsbad, CA2
- Florham Park, NJ2
- Needham, MA1
- Newton, MA1
- Rochester, NY1
- Basking Ridge, NJ1
- Emeryville, CA1
- Irving, TX1
- Thousand Oaks, CA1
- Piscataway, NJ1
- New York, NY1
- Arlington Heights, IL1
- Gaithersburg, MD1
- South Plainfield, NJ1
- Pennington, NJ1
- San Francisco, CA1
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).